Developing therapies for type 1 diabetes

Diamyd® and Remygen® are drugs in clinical development phase,
aimed to preserve and restore the body's insulin production.

 

We are on the verge of radically changing how autoimmune diabetes should be treated. The antigen-specific immunotherapy Diamyd® targets individuals who carry a specific gene type found in up to 40% of all people who suffer from or are at risk of autoimmune diabetes, a textbook example of precision medicine. This is a great discovery and a paradigm shift in the field.

Ulf Hannelius
President and CEO, Diamyd Medical AB

ABOUT DIAMYD MEDICAL

Diamyd Medical is a clinical-stage diabetes company active in the field of pharmaceutical development.

We develop two novel disease-modifying drugs: the antigenspecific immunotherapy Diamyd® and the oral regenerative and immunomodulatory therapeutic Remygen®.

Diamyd® and Remygen® are evaluated in ongoing clinical studies. The therapies target the underlying causes of diabetes, dysfunction and loss of the pancreas's insulin-producing cells.

Diamyd Medical’s shares are traded on Nasdaq First North Growth Market, ticker DMYD B.

 

ORGANISATION

Internal core competences constitute Diamyd Medical's core employees in collaboration with a global network of clinics, researchers and production units. Further expertise, including analysis- and laboratory services are contracted as needed during specific project phases. The model is based on long-term collaborations and cost efficiency.

Order GAD for preclinical research

GAD PRODUCTS